{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu J"],"funding":["Basic and Applied Basic Research Foundation of Guangdong Province","the Scientific and Technological Planning Project of Guangzhou City"],"pagination":["37"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11853526"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["<h4>Background</h4>m6A methylation modification is a new regulatory mechanism involved in tumorigenesis and tumor-immunity interaction. However, its impact on glioma immune microenvironment and clinical outcomes remains unclear.<h4>Methods</h4>Comprehensive expression profiles of 18 m6A regulators were used to identify molecular subtypes exhibiting distinct m6A modification patterns in 1673 glioma samples sourced from public datasets. A multi-genes signature was constructed for predicting clinical outcomes and response to immunotherapy in glioma patients. Immunohistochemistry and cellular experiments were performed for validation.<h4>Results</h4>Two m6A subtypes of gliomas were identified. The m6A-low-risk subtype was characterized by paucity of immune infiltrates; While the m6A-high-risk "],"journal":["BMC medical genomics"],"pubmed_title":["m6A regulator-based molecular classification and hub genes associated with immune infiltration characteristics and clinical outcomes in diffuse gliomas."],"pmcid":["PMC11853526"],"funding_grant_id":["202201010515","2022A1515111118","2023A04J1782"],"pubmed_authors":["Li D","Hu W","Lu J","Sai K","Chen S","Jiang P"],"additional_accession":[]},"is_claimable":false,"name":"m6A regulator-based molecular classification and hub genes associated with immune infiltration characteristics and clinical outcomes in diffuse gliomas.","description":"<h4>Background</h4>m6A methylation modification is a new regulatory mechanism involved in tumorigenesis and tumor-immunity interaction. However, its impact on glioma immune microenvironment and clinical outcomes remains unclear.<h4>Methods</h4>Comprehensive expression profiles of 18 m6A regulators were used to identify molecular subtypes exhibiting distinct m6A modification patterns in 1673 glioma samples sourced from public datasets. A multi-genes signature was constructed for predicting clinical outcomes and response to immunotherapy in glioma patients. Immunohistochemistry and cellular experiments were performed for validation.<h4>Results</h4>Two m6A subtypes of gliomas were identified. The m6A-low-risk subtype was characterized by paucity of immune infiltrates; While the m6A-high-risk ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-03T23:44:21.99Z","creation":"2025-04-03T23:44:21.99Z"},"accession":"S-EPMC11853526","cross_references":{"pubmed":["39994800"],"doi":["10.1186/s12920-025-02104-9"]}}